Allspring Global Investments Holdings LLC cut its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) by 74.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,101 shares of the company's stock after selling 203,237 shares during the period. Allspring Global Investments Holdings LLC owned about 0.19% of iTeos Therapeutics worth $1,316,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. increased its stake in iTeos Therapeutics by 106.5% in the first quarter. BlackRock Inc. now owns 3,331,313 shares of the company's stock valued at $107,203,000 after purchasing an additional 1,718,085 shares during the last quarter. State Street Corp boosted its holdings in shares of iTeos Therapeutics by 124.3% in the first quarter. State Street Corp now owns 1,711,891 shares of the company's stock valued at $55,089,000 after acquiring an additional 948,540 shares during the period. Vanguard Group Inc. boosted its holdings in shares of iTeos Therapeutics by 39.1% in the first quarter. Vanguard Group Inc. now owns 1,476,042 shares of the company's stock valued at $47,499,000 after acquiring an additional 415,232 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of iTeos Therapeutics by 146.7% in the second quarter. JPMorgan Chase & Co. now owns 559,299 shares of the company's stock valued at $11,522,000 after acquiring an additional 332,625 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in shares of iTeos Therapeutics by 276.9% during the second quarter. AQR Capital Management LLC now owns 445,110 shares of the company's stock worth $9,169,000 after purchasing an additional 327,025 shares during the period.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS opened at $21.70 on Friday. The stock has a fifty day moving average price of $19.76 and a 200 day moving average price of $21.06. iTeos Therapeutics, Inc. has a 1-year low of $16.21 and a 1-year high of $38.14. The company has a market cap of $771.98 million, a PE ratio of 3.15 and a beta of 1.38.

iTeos Therapeutics Company Profile

(Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Featured Stories

• Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
• MarketBeat Week in Review – 1/16 – 1/20
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.